Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy
Case ID:
TAB-2772
Web Published:
12/6/2022
CDC researchers have developed an
in vitro
model system designed to simulate early-stage
Mycobacterium tuberculosis
infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and
in vitro
candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic
in situ
granuloma formation in a controllable
in vitro
environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Novel_In_Vitro_Granuloma_Mod el_for_Studying_Tuberculosis_and_Drug_Efficacy
Keywords:
AC4XXX
AC5XXX
ACXXXX
ANTIGENS
AXXXXX
CDC Docket Import
CDC Docket Import CDC Prosecuting
DA3XXX
DAXXXX
DC4XXX
DCXXXX
DDXXXX
DEXXXX
diagnostic
DXXXXX
Granuloma
Human
IA3XXX
Identification
Latent
Methods
Model
OID-NCHHSTP-DTE
TUBERCULOSIS
Vitro
VJXXXX
WBXXXX
WFXXXX
WIXXXX
WMXXXX
XHXXXX
YBXXXX
YFXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Jeremiah Mitzelfelt
LPM
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov